- Home
- Products
- Customized ADCs
- CA9
- Anti-CA9 (Girentuximab)-MC-MMAF ADC
Anti-CA9 (Girentuximab)-MC-MMAF ADC (CAT#: ADC-W-742)
This ADC product is comprised of an anti-CA9 monoclonal antibody conjugated via a MC linker to MMAF. The MMAF is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, MMAF binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.
- ADC Target
- ADC Antibody
- ADC Linker
- ADC payload drug
- Name
- CA9
- Alternative Names
- CA9; carbonic anhydrase IX; carbonic anhydrase 9; CAIX; carbonic dehydratase; MN; RCC associated protein G250; pMW1; CA-IX; P54/58N; membrane antigen MN; carbonate dehydratase IX; RCC-associated antigen G250; RCC-associated protein G250; renal cell carcin
- Target Entrez Gene ID
- 768
- Target UniProt ID
- Q16790
- Overview
- Carbonic anhydrases (CAs) are a large family of zinc metalloenzymes that catalyze the reversible hydration of carbon dioxide. They participate in a variety of biological processes, including respiration, calcification, acid-base balance, bone resorption, and the formation of aqueous humor, cerebrospinal fluid, saliva, and gastric acid. They show extensive diversity in tissue distribution and in their subcellular localization. CA IX is a transmembrane protein and is one of only two tumor-associated carbonic anhydrase isoenzymes known. It is expressed in all clear-cell renal cell carcinoma, but is not detected in normal kidney or most other normal tissues. It may be involved in cell proliferation and transformation. This gene was mapped to 17q21.2 by fluorescence in situ hybridization, however, radiation hybrid mapping localized it to 9p13-p12.
- Overview
- Chimeric Anti-CA9 IgG1-kappa antibody, Girentuximab
- Generic name
- Girentuximab
- Host animal
- Mouse
- Species Reactivity
- Human
- Name
- MC (maleimidocaproyl)
- Description
- Noncleavable linkers, is considered noncleavable-meaning linker cleavage, and payload release does not depend on the differential properties between the plasma and some cytoplasmic compartments. Instead, the release of the cytotoxic drug is postulated to occur after internalization of the ADC via antigen-mediated endocytosis and delivery to lysosomal compartment, where the antibody is degraded to the level of amino acids through intracellular proteolytic degradation.
- Name
- MMAF
- Description
- Derived from Auristatin,are water-soluble dolastatin analogs of dolastatin 10. Dolastatin 10 belongs to dolastatin family and it can powerfully bind to tubulin, thus inhibiting polymerization mediated through the binding to the vinca alkaloid binding domain, and causes cell to accumulate in metaphase arrest.
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-CD70-MCC-DM1 ADC (CAT#: ADC-W-487)
- Anti-RhD (Roledumab)-SPDB-DM4 ADC (CAT#: ADC-W-1731)
- Anti-ACVR2B (Bimagrumab)-SPDB-DM4 ADC (CAT#: ADC-W-651)
- Anti-GD2 (Dinutuximab)-SPDB-DM4 ADC (CAT#: ADC-W-2007)
- Anti-CD19 (Blinatumomab)-SMCC-DM1 ADC (CAT#: ADC-W-776)
- Anti-GUCY2C (clone 5F9)-VC-MMAE ADC (CAT#: ADC-W-209)
- Anti-EGFR (J2898A)-SMCC-DM1 ADC (CAT#: ADC-W-495)
- Anti-GD2 (Dinutuximab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-2009)
- Anti-LTA (Pateclizumab)-SPDB-DM4 ADC (CAT#: ADC-W-1533)
- Anti-MSTN (Stamulumab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-1607)
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for ADC-W-742. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
Same Linker
Same Payload
| CAT# | Product Name | Linker | Payload |
| ADC-W-745 | Anti-CA9 (Girentuximab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
| ADC-W-741 | Anti-CA9 (Girentuximab)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
| ADC-W-318 | Anti-CA9-MCC-MMAE ADC | MCC (Maleimidomethyl cyclohexane-1-carboxylate) | MMAE (Monomethyl auristatin E) |
| ADC-W-740 | Anti-CA9 (Girentuximab)-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
| ADC-W-475 | Anti-CA9-VC-MMAE ADC | VC (valine-citrulline) | MMAE (Monomethyl auristatin E) |
| CAT# | Product Name | Linker | Payload |
| ADC-W-452 | Anti-CD70 (clone 1F6)-Mc-MMAF ADC | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
| ADC-W-2612 | Anti-MS4A1 (Rituximab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-2606 | Anti-ITGB3 (Tadocizumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-478 | Anti-ENPP3-Mc-MMAF ADC | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
| ADC-W-518 | Anti-TM4SF1 ( clone 2A7A)-Mc-LP2 ADC | Mc (maleimidocaproyl) | LP2 (chemical name mc-3377) |
| CAT# | Product Name | Linker | Payload |
| ADC-W-2544 | Anti-CD44 (Bivatuzumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-2573 | Anti-SLC34A2 (Lifastuzumab )-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-2600 | Anti-GPNMB (Glembatumumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-2591 | Anti-EGFR (Cetuximab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-2612 | Anti-MS4A1 (Rituximab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
